1. Home
  2. EVOXU vs XOMAP Comparison

EVOXU vs XOMAP Comparison

Compare EVOXU & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVOXU

Evolution Global Acquisition Corp Units

N/A

Current Price

$10.18

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMAP

XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

HOLD

Current Price

$25.47

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVOXU
XOMAP
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
14
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
EVOXU
XOMAP
Price
$10.18
$25.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.7K
2.0K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.05
$25.14
52 Week High
$10.30
$27.30

Technical Indicators

Market Signals
Indicator
EVOXU
XOMAP
Relative Strength Index (RSI) 46.86 48.87
Support Level $10.15 $25.31
Resistance Level $10.27 $25.58
Average True Range (ATR) 0.01 0.05
MACD -0.00 0.01
Stochastic Oscillator 11.11 51.56

Price Performance

Historical Comparison
EVOXU
XOMAP

About EVOXU Evolution Global Acquisition Corp Units

Evolution Global Acquisition Corp is a blank check company.

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.

Share on Social Networks: